CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 43 enrolled
Drug / intervention
3BNC117-LS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03254277
NCT03254277Phase 1Completed
CompareCT.gov

A Phase 1 First-in-human Study of the Safety and Pharmacokinetics of 3BNC117-LS in HIV-infected and HIV-uninfected Individuals

Rockefeller University·interventional·Posted Aug 18, 2017·Updated May 20, 2026

In Brief

A Phase 1 clinical trial evaluating 3BNC117-LS and Placebo for Human Immunodeficiency Virus. Completed, enrolled 43 participants across 1 site.

Detailed Summary

The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 18, 2017
Enrollment StartSep 13, 2017
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.9 years ago

Interventions

3BNC117-LSdrug

Intravenous infusion of 3BNC117-LS

Placebodrug

Placebo